FIELD: biotechnology.
SUBSTANCE: proposed is a shuttle for the blood-brain barrier. The shuttle is comprised of a full-length IgG antibody directed at a target in the brain, a linker, and one Fab bound to a transferrin receptor. Fab is linked with the C-terminus of the full-length IgG antibody by a linker.
EFFECT: invention makes it possible to efficiently transport medicinal products to the brain.
3 cl, 37 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND CONTAINING THERAPEUTIC ENZYME AND TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING LINKER | 2022 |
|
RU2811100C1 |
| ANTIBODIES AGAINST TRANSFERRIN RECEPTOR HAVING INDIVIDUALIZED AFFINITY | 2016 |
|
RU2729416C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2718990C1 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2697098C1 |
| BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
| BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
| METHOD FOR TREATMENT OR PREVENTION OF STROKE | 2015 |
|
RU2744909C2 |
| HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
